



# CSL Research Acceleration Initiative

Applications close 23<sup>rd</sup> February 2023

## WHY COLLABORATE WITH CSL?



**Global** capabilities on your doorstep.



**Work** with one of the world's leading biotech companies.



**Funding** for successful proposals.



**Access** to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise.



**Accelerate** translation of your research to deliver new therapies to patients.

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL's **Research Acceleration Initiative** aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas.

**Successful applicants** will receive up to USD \$200k p.a. for up to 2 years (max USD \$400k funding). Interested researchers are invited to email Yoojin Park at [research3@yonsei.ac.kr](mailto:research3@yonsei.ac.kr) for information session webinar links and online application instructions.


Webinars may also be accessed here:

[1st February 2:00pm AEDT](#) or

[3rd February 12:00pm AEDT](#).

Researchers who wish to apply are required to submit a non-confidential, 300 word online abstract by 23<sup>rd</sup> February 2023.

The 2023 Research Acceleration Initiative will focus on research proposals that align with a **CSL Therapeutic Area** and are amenable to or include a **Modality** as illustrated below. Please see over page for specific **Focus Areas**.



# CSL Research Acceleration Initiative



## Focus Areas

CSL is seeking applications that align with a **CSL Therapeutic Area** and are amenable to or include a **CSL Modality** in the following **Focus Areas**:

### IMMUNOLOGY

#### Autoimmune diseases (AID)

Novel targets or biologic therapies for the treatment of AIDs including primary Sjögren's syndrome, systemic sclerosis, inflammatory idiopathic myopathies (including dermatomyositis) and autoimmune skin blistering diseases. We are seeking:

- Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF-family members
- Novel targets or biologic therapies involved in B cell depletion or B cell regulation
- Novel targets or biologic therapies involved in T cell regulation, T cell tolerance and T regulatory cell modulation

#### Alternatives to plasma-derived intravenous immunoglobulin (IVIG)

Synthetic or recombinant solutions to IVIG that are independent of plasma

### CARDIOVASCULAR AND METABOLIC

#### Myocarditis

Novel targets or biologic therapies for myocarditis

#### Dilated cardiomyopathy

Novel targets or biologic therapies for inflammatory dilated cardiomyopathy

#### Rare lipid disorders

Novel targets or biologic therapies (including gene therapies) for rare lipid disorders e.g. homozygous familial hypercholesterolemia

#### Severe forms of atherosclerosis

Novel targets or biologic therapies for severe atherosclerosis

### ORAL DELIVERY

Technologies enabling oral delivery of biologics (e.g. antibodies and other protein therapeutics)

### HEMATOLOGY

#### Hemorrhagic stroke

- Novel biologic targets or therapies for the treatment of subarachnoid hemorrhage and intracerebral hemorrhage
- Biomarker or omics approaches for patient stratification and drug discovery

#### Acute ischemic stroke

- Novel biologic targets or therapies for the treatment of acute ischemic stroke, in particular anti-(thrombo-) inflammatory approaches as an adjunct to endovascular thrombectomy and pharmacological thrombolysis (tPA)
- Biomarker or omics approaches for patient stratification and drug discovery

#### Acute thrombosis (venous and arterial thrombosis)

Novel biologic therapies for targeted fibrinolysis / thrombolysis with increased safety and / or efficacy vs. standard of care in acute thrombotic conditions, in particular acute ischemic stroke and pulmonary embolism

### TRANSPLANT

#### Chronic lung allograft dysfunction (CLAD)

- Novel biologic therapies or targets to prevent or treat CLAD, including approaches to establish tolerance / novel immunomodulation strategies
- Novel biomarkers for CLAD

#### Hematopoietic stem cell transplant (HSCT)

- Novel biologic therapies for the treatment and prevention of acute and chronic GvHD, including approaches to establish tolerance / novel immunomodulation strategies
- Novel biologic therapies that improve efficacy / safety of HSCT

#### Cardiovascular allograft vasculopathy (CAV)

- Novel biologic therapies for the treatment of CAV
- Animal models of CAV

### RESPIRATORY

#### Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)

- Novel biologic therapies or targets to treat IPF and PPF
- Omics approaches for patient stratification and drug discovery

#### Community acquired pneumonia (CAP)-associated complications

- Novel biologic therapies or targets to treat CAP-associated complications including acute respiratory distress syndrome (ARDS), sepsis, and acute kidney injury (AKI)
- Omics approaches for patient stratification and drug discovery

### VACCINES

#### mRNA and lipid nanoparticle platform

Innovative research addressing improved delivery, formulation, stabilization (5°C / room temperature), shelf-life extension and manufacturing technologies

#### Influenza virus antigen purity and yield enhancement

Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture

#### Proven adjuvant technology

Partnerships with our proprietary adjuvant MF59®

### GENE THERAPY

- *In vivo* kill switch or suicide switch
- Modulation of transgene expression *in vivo*
- Novel methods to select gene modified hematopoietic stem cells
- Novel gene therapies or gene therapy targets aligned with CSL's Therapeutic Areas
- Non-viral *in vivo* delivery of ribonucleoproteins

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail [RAI@csl.com.au](mailto:RAI@csl.com.au) to discuss.